gallium citrate ga 67
Approved
May 17, 1976
Gallium citrate Ga 67 is the citrate salt of the radioisotope gallium Ga 67. Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metastatic tumors and focal sites of inflammation, allowing scintigraphic localization. Ga-67 scintigraphy (GS) cannot differentiate between tumor and acute inflammation. Gallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. — NCATS
Clinical trial activity
8 trials · 8 clinical orgs · 3 marketing orgs
Earliest trial started May 1, 2007 (NCT00477503)
Timeline
1970s
- May 17, 1976
Lantheus Medical Imaging — Earliest FDA Approval
- May 17, 1976
Lantheus Medical Imaging — NDA Secondary Org
- May 17, 1976
Lantheus Medical Imaging — NDA Organization
- Dec 16, 1977
General Electric — NDA Secondary Org
- Feb 1, 1979
Curium Pharma — NDA Secondary Org
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- LactotransferrinBINDING AGENT
LTF binding agent
Approval history
- approvedPriority reviewMay 17, 1976
Chemistry & pharmacology
SMILES
[67Ga+3]- Mol. weight
- 258.82 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Imaging
- 67-gallium
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL2110553 ↗
- NCATS99T03J52W0 ↗
- ChEMBLCHEMBL1200994 ↗
Also known as
- 67ga
- 67ga
- (68)ga-citrate
- 68gallium citrate
- ga-67 citrate
- gallium-67 citrate
- gallium-67 citrate
- gallium-67 citrate
- gallium-67 citrate
- gallium-67-citrate
- gallium(67) citrate
- gallium (67 ga) citrate
- gallium (67 ga) citrate
- gallium (67ga) citrate
- gallium citrate
- gallium citrate
- gallium citrate
- gallium citrate
- gallium citrate (1:1); 67ga-labeled
- gallium citrate (67ga)
- gallium citrate, 67ga-labeled
- gallium citrate ga 67
- gallium citrate ga 67
- gallium citrate ga 67
- gallium citrate ga 67
- gallium citrate ga-67
- gallium citrate ga-67
- gallium citrate ga-67
- neoscan
- neoscan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04139395 | Phase 3 | Jan 15, 2019 | Stanford University |
| NCT03669614 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2018 | Aridis Pharmaceuticals, Inc. |
| NCT03123289 | Phase 2 | Mar 6, 2017 | Rutgers University |
| NCT03116945 | Phase 2 | Jun 1, 2016 | Radiological Society of North America, Rutgers University |
| NCT02776891 | N/A | May 1, 2016 | University of California, San Francisco |
| NCT02391025 | Early Phase 1 (Phase 1) | May 28, 2015 | Department of Defense, University of California, San Francisco |
| NCT01951300 | N/A | Sep 30, 2013 | University of Turku |
| NCT00477503 | Phase 1 | May 1, 2007 | University of Texas at Houston |
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rutgers University | Academic/Hospital | 2 | 2 | 1 | 2016 |
| University of California, San Francisco | Academic/Hospital | 2 | 2 | 2 | 2015 |
| Aridis Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2018 |
| Department of Defense | Government | 1 | 0 | 1 | 2015 |
| Radiological Society of North America | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2007 |
| University of Turku | Academic/Hospital | 1 | 1 | 1 | 2013 |
Marketing (4)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Curium Pharma | For profit | NDA2 | Feb 1, 1979 |
| General Electric | For profit | NDA2 | Dec 16, 1977 |
| Lantheus Medical Imaging | For profit | NDA2 | May 17, 1976 |
| Lantheus Medical Imaging | For profit | NDA | May 17, 1976 |